GlassScriptPhysician profile
Rajesh Prasad
NPI 1558471540
$9,442.26
in general payments reported to CMS, 2019-2025
33 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,790 · 2020: $595 · 2021: $1,654 · 2022: $1,488 · 2023: $1,139 · 2024: $1,201 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,377 · Travel and Lodging: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,377.38 |
| Travel and Lodging | $537.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,146.71 | 2020-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $922.94 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $870.57 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $862.13 | 2021-2025 | Verquvo |
| Amgen INC. | $756.25 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $703.01 | 2019-2025 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $683.73 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $537.82 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.18 | 2019-2025 | Jardiance |
| Biotronik INC. | $326.56 | 2022-2025 | Acticor 7 Vr-T Dx, Amvia Edge, Solia |
| Sanofi-Aventis U.S. LLC | $313.41 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $219.25 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $204.24 | 2019-2020 | |
| Bardy Diagnostics, INC. | $180.69 | 2021 | |
| Pfizer INC. | $168.85 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $159.77 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Edwards Lifesciences Corporation | $152.58 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $125.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.84 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $116.78 | 2024 | Arcalyst |
| Abbott Laboratories | $77.31 | 2019-2021 | |
| Amarin Pharma, INC. | $69.16 | 2019-2021 | |
| Esperion Therapeutics, INC. | $67.50 | 2020-2021 | |
| Vifor Pharma, INC. | $55.53 | 2019 | |
| Baxter Healthcare | $40.77 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Glaxosmithkline, LLC. | $39.02 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $27.95 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $26.28 | 2023 | Arcalyst |
| Allergan, INC. | $25.48 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.00 | 2019 | |
| Heartflow, INC. | $22.95 | 2024 | |
| Amryt Pharma Holdings LTD | $16.41 | 2021 | |
| Octapharma USA, INC. | $15.59 | 2025 | Balfaxar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Prasad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.